Thalidomide-O-amido-C4-NH2 is primarily utilized in the field of medicinal chemistry and drug development. It serves as a key intermediate in the synthesis of targeted therapeutic agents, particularly in the design of proteolysis-targeting chimeras (PROTACs). These molecules are engineered to degrade specific disease-causing proteins by leveraging the ubiquitin-proteasome system. In cancer research, this compound is explored for its potential to create drugs that selectively degrade oncogenic proteins, offering a novel approach to cancer treatment. Additionally, it is investigated in the development of immunomodulatory drugs, which can modulate the immune system to treat autoimmune diseases or enhance anti-tumor immunity. Its unique structure allows for conjugation with various ligands, enabling the precise targeting of proteins of interest. This versatility makes it a valuable tool in advancing precision medicine and developing next-generation therapies.